CV Therapeutics to Announce 2006 Second Quarter Financial Results on Thursday, August 3, 2006
July 20 2006 - 5:00PM
PR Newswire (US)
PALO ALTO, Calif., July 20 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) today announced that it will
release second quarter financial results for 2006 after the market
closes on Thursday, August 3, 2006. Company management will webcast
a conference call at 5:00 p.m. EDT, 2:00 p.m. PDT, on the Company's
website. To access the live webcast, please log on to the Company's
website at http://www.cvt.com/ and go to the Investor Information
section. Alternatively, domestic callers may participate in the
conference call by dialing 888-370-6121, and international callers
may participate in the conference call by dialing 706-679-7163.
Webcast and telephone replays of the conference call will be
available approximately two hours after the completion of the call
through Thursday, August 10, 2006. Domestic callers can access the
replay by dialing 800-642-1687, and international callers can
access the replay by dialing 706-645-9291; the PIN access number is
3317478. About CV Therapeutics CV Therapeutics, Inc., headquartered
in Palo Alto, California, is a biopharmaceutical company focused on
applying molecular cardiology to the discovery, development and
commercialization of novel, small molecule drugs for the treatment
of cardiovascular diseases. CV Therapeutics' approved products
include Ranexa(R) (ranolazine extended- release tablets) and
ACEON(R) (perindopril erbumine) Tablets. Ranexa is indicated for
the treatment of chronic angina in patients who have not achieved
an adequate response with other antianginal drugs, and should be
used in combination with amlodipine, beta-blockers or nitrates. In
addition, CV Therapeutics co-promotes ACEON(R), an ACE inhibitor,
for reduction of the risk of cardiovascular mortality or nonfatal
myocardial infarction in patients with stable coronary artery
disease and treatment of essential hypertension. CV Therapeutics
also has other clinical and preclinical drug development candidates
and programs, including regadenoson, which is being developed for
potential use as a pharmacologic stress agent in myocardial
perfusion imaging studies. Regadenoson has not been approved for
marketing by any regulatory authorities. DATASOURCE: CV
Therapeutics, Inc. CONTACT: investors, Christopher Chai, Vice
President, Treasury and Investor Relations, +1-650-384-8560, or
media, John Bluth, Senior Director, Corporate Communications,
+1-650-384-8850, both of CV Therapeutics, Inc. Web site:
http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Oct 2023 to Oct 2024